Senestech (SNES) investor relations material

Key strategic highlights

• Focus shifted from research-led to commercial execution, emphasizing direct customer relationships, recurring revenue, and data-driven decision making.

• Brought Amazon sales in-house, launched new website, and introduced assessment services, resulting in record revenue, e-commerce, subscriptions, gross profit, and margins in Q2.

• Evolve and ContraPest products target rodent birth rates, offering a non-lethal, EPA-compliant alternative to traditional poisons.

• Market opportunity estimated at $2B in the U.S. and $4.5B globally, with regulatory and consumer trends favoring sustainable solutions.

• Three growth engines: e-commerce, B2B sales, and expansion through services and partnerships, each reinforcing the others.

Operational and financial performance

• Q2 revenue grew 56% sequentially to $770,000, with e-commerce nearly tripling and Amazon sales up fivefold.

• Gross margin reached a record 76.6%, driven by pricing discipline, channel control, and recurring revenue.

• Subscription revenue nearly doubled sequentially and year-over-year, indicating growing customer adoption.

• Operating expenses declined modestly despite investments in sales and brand, improving net loss and adjusted EBITDA loss.

• Clean balance sheet with no restrictive covenants; capital focused on revenue growth and margin maintenance.

Market and competitive positioning

• Only commercial provider of EPA-compliant rodent birth control in the U.S., with a defensible moat built on regulatory, patent, and brand advantages.

• Regulatory tailwinds: increasing restrictions on rodenticides in California and other states, rising demand for sustainable pest control.

• Field evidence shows up to 95% reduction in rodent activity across multiple customer settings.

• Assessment services launched to deepen customer relationships and generate incremental revenue.

• New leadership and sales organization prioritizing verticals and ROI-driven B2B expansion.